Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$CWBHF Golden cross forming on daily chart...
https://schrts.co/GSVuYNFK
BRLL 9.7M VOLUME 10 DAY AVG_4M .076 +26.67%
AMAM 116M VOLUME 10 DAY AVG_500K $4.54 +1,007.59%
AMAM 111M VOLUME 10 DAY AVG_500K $4.44 +983%
AMAM 47M VOLUME 10 DAY AVG_500K $4.21 + 927%
AMAM 46M VOLUME 10 DAY AVG_500k $3.80 +827%
*MAMA, I MEAN AMAM
$MASN earnings news - https://finance.yahoo.com/news/maison-luxe-reports-revenues-approximately-154300001.html
$JUPW News: Jupiter Wellness Issues Letter to Shareholders and Corporate Update
JUPITER, FL / ACCESSWIRE / December 6, 2022 / Jupiter Wellness, Inc. (NASDAQ:JUPW), a wellness company focused on hair, skin, and sexual wellness, issued a Letter to Shareholders today to provide a corporate update since its last report in September.
Dear Shareholders,
I would like to take this opportunity to review the significant progress made by your company since the last Letter to Shareholders dated September 15. We have launched or restarted two clinical trials for tinnitus and eczema, both conditions with large patient populations. We have entered the potentially lucrative market of Female Sexual Wellness and obtained or added to our intellectual property portfolio with the addition of our hair loss therapy. We finally had our topical treatment for psoriasis and vitiligo approved by the "FDA of India" and just announced the market launch in India. And lastly, we announced record revenues for the Nine Months ending September 30 vs. the corresponding period in 2021.
We have compiled a quick summary of recent developments and an overview of our products and their current disposition - whether already on the market and generating revenues, currently in clinical trials, or in development:
Jupiter Wellness Corporate Development Highlights
Signed an exclusive licensing agreement with Rejoy, Inc. to develop prescription products for the treatment of nipple neuropathies and associated sexual problems in women that have been treated for breast cancer. The exclusive license includes issued patents and technology, including all formulations. In initial clinical studies, one topical formulation enhanced nipple sensitivity and alleviated associated sexual problems such as increased female sexual lubrication and improved overall orgasmic response. The Company plans to file for a pre-IND meeting with the US FDA within the next 12 months and intends to seek Orphan Drug Designation (ODD). The benefits of an ODD include up to a 50% tax credit for clinical trials that qualify, waiver of Prescription Drug User Fee Amendments (PDFUA) application fees, including the New Drug Application (NDA) and Biologics License Application (BLA), eligibility for Federal research grants and a 7-year market exclusivity.
United States Patent and Trademark Office (USPTO) granted a notice of allowance for patent application No. 16/747,685, titled "Minoxidil Adjuvant Therapies." The patent encompasses the composition and methods for inducing (up-regulating) the expression of sulfotransferases in the hair follicles on the scalp. It has been shown that the induction of the sulfotransferase enzyme in hair follicles increases the sulfonation capacity of minoxidil, thereby increasing the response level to oral and topical minoxidil in the treatment of alopecia.
Announced the initiation of a triple-blinded clinical study evaluating a possible treatment for tinnitus. Up to 15% of patients recovering from COVID-19 have experienced post-acute COVID-19-induced tinnitus. During the COVID-19 pandemic, Jupiter Wellness scientists identified a novel pathway for the treatment of COVID-19-induced tinnitus and possibly subjective tinnitus. The discovery led to a patent recently filed by Jupiter Wellness for the use of dopamine receptor modulation for the treatment of tinnitus. The Company launched a study to investigate if dopamine receptor modulation can be used effectively to treat COVID-19-induced tinnitus (https://clinicaltrials.gov/ct2/show/NCT05507372). Currently, there is no effective treatment available for patients suffering from tinnitus.
Company's Photocil product (branded as PhotoFirst in India) has been approved by the CDSCO for sale in India. The Central Drugs Standard Control Organisation (CDSCO), under the Directorate General of Health Services, Ministry of Health & Family Welfare, is the National Regulatory Authority (NRA) of India. Photocil is a topical product that filters UV rays from the sun to allow only the therapeutic UV spectrum to penetrate the skin and is used for the treatment of psoriasis and vitiligo. After this market approval, Eris Oaknet Healthcare Pvt Ltd (Eris Oaknet) and Cosmofix Technovation Pvt Ltd (Cosmofix) had market launch meetings for Photocil products for the Indian market in November. The incidence of psoriasis among total skin patients in India ranged between 0.44 and 2.2%, with overall incidence of 1.02% (hyperlink: https://ijdvl.com/psoriasis-in-india-prevalence-and-pattern/). The overall prevalence of vitiligo (hyperlink: https://pubmed.ncbi.nlm.nih.gov/4054593/ ) is about 5 per 1,000 individuals. India has a population of 1.412 billion.
Announced that it has begun the application process to dual list its shares on Upstream, the revolutionary trading app for digital securities and NFTs powered by Horizon Fintex ("Horizon") and MERJ Exchange Limited ("MERJ"). The planned dual listing on Upstream is designed to provide Jupiter Wellness the opportunity to access a global, digital-first investor base that can trade using USDC digital currency along with credit, debit, PayPal, and USD, unlocking liquidity and enhancing price discovery while globalizing the opportunity to invest in Jupiter Wellness.
Re-opened patient enrollment in a clinical trial to evaluate the superiority of JW-100, a novel cannabidiol topical cream, in a head-to-head study against EUCRISA, an FDA Approved topical treatment for eczema developed by Pfizer. The initial study was put on hold to solve stability issues which were resolved in the original JW-100 formulation.
The Company reported $1.57 million in revenues for the three months that ended September 30, 2022, compared to $688K for the same period in 2021, a 228% increase. In addition to the revenues booked in the Third Quarter, Jupiter Wellness's wholly-owned subsidiary, SRM Entertainment, received $3.6 million in guaranteed purchase orders, with revenues realized once orders are shipped. For the Nine Months that ended Sept. 30, revenues were $5.29 Million vs. $1.33 Million, representing a 398% increase over the First Nine Months of 2021.
On October 25, Jupiter Wellness Acquisition Corp., of which Jupiter Wellness is the sponsor and owns a considerable stake, entered into a definitive business combination agreement with Chijet Motor Company, Inc., which is developing next-generation electric vehicles and expanding its manufacturing capabilities. The deal is expected to be consummated in the next three months.
The Company retired an additional 391,000 shares to treasury from our share buyback program that ended in June.
Product Overview of Jupiter Wellness Products
Minoxidil Booster (TM) - Topical treatment designed to improve Minoxidil efficacy (Approved and on the market)
Photocil (TM) - Topical treatment for psoriasis and vitiligo (Licensed and on the market)
NoStingz (TM) - Topical protection from jellyfish, sea lice, and UVA/UVB rays (Approved and on the market)
JW-100 - Topical treatment of eczema (Currently in development)
JW-300 - Topical treatment of first-degree burns and sun exposure (Currently in development)
JW-400 - Topical treatment of cold sores (Currently in development)
JW-500 - Topical treatment for female sexual wellness (Currently in development)
JW-600 - Treatment for COVID-19-induced tinnitus (Clinical trials underway)
As we head into the end of 2022, we look forward to capitalizing on the progress we have made in building a foundation for continued revenue growth, monetizing our clinical trial programs, building profitability, and enhancing shareholder value.
Please accept my thanks and the gratitude of our entire executive team for your continued support of Jupiter Wellness.
Happy Holidays.
/s/ Brian John
Chief Executive Officer, Jupiter Wellness
About Jupiter Wellness
Jupiter Wellness is a diversified company that supports health and wellness by researching and developing over-the-counter (OTC) products and intellectual property. The Company's product pipeline addresses a range of conditions, including hair loss, eczema, burns, and sexual wellness. Revenue is generated through the sales of OTC and consumer products, contract research agreements, and licensing royalties.
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for Email Alerts at https://jupiterwellness.com/email-alerts/ and by following Jupiter Wellness on Twitter and LinkedIn.
Media Contact
Phone: 561-244-7100
Email: media@jupiterwellness.com
Investor Contact
Phone: 561-244-7100
Email: investors@jupiterwellness.com
Forward-Looking Statements
This communication contains forward-looking statements regarding Jupiter Wellness, including, the anticipated timing of studies and the results and benefits thereof. You can generally identify forward-looking statements by the use of forward-looking terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "explore," "evaluate," "intend," "may," "might," "plan," "potential," "predict," "project," "seek," "should," or "will," or the negative thereof or other variations thereon or comparable terminology. These forward-looking statements are based on each of the Company's current plans, objectives, estimates, expectations, and intentions and inherently involve significant risks and uncertainties, many of which are beyond Jupiter Wellness' control. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties and other risks and uncertainties affecting Jupiter Wellness, including those described from time to time under the caption "Risk Factors" and elsewhere in Jupiter Wellness' Securities and Exchange Commission (SEC) filings and reports, including Jupiter Wellness' Annual Report on Form 10-K for the year ended December 31, 2021, and future filings and reports by Jupiter Wellness. Moreover, other risks and uncertainties of which the combined company is not currently aware may also affect each of the companies' forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. Investors are cautioned that forward-looking statements are not guarantees of future performance. The forward-looking statements made in this communication are made only as of the date hereof or as of the dates indicated in the forward-looking statements and reflect the views stated therein with respect to future events at such dates, even if they are subsequently made available by Jupiter Wellness on its website or otherwise. Jupiter Wellness undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations, or other circumstances that exist after the date on which the forward-looking statements were made.
SOURCE: Jupiter Wellness Inc.
View source version on accesswire.com:
https://www.accesswire.com/730279/Jupiter-Wellness-Issues-Letter-to-Shareholders-and-Corporate-Update
$PVSP We also invested in a small Korea based research entity, KRTL, to establish an early foothold in the rapidly expanding world of medical fungi, with a specific focus on Psilocybin. It is an entry to a large database of related research, various research entities actively involved in related development projects and provides Pervasip with a perfect perch to look at various fungi opportunities across the globe.
$PVSP As one of Washington’s original cannabis brands, Artizen - branded products are the all-time fourth best-selling in Washington across all product categories, and the all-time third in flower. The commitment to quality and consistency behind Artizen™ has built a substantial following, fueling more than $69 million in wholesale sales to a distribution network with more than 200 retailers, corresponding to more than $200 million in retail value since inception in 2015. ZAM is looking to expand its service into Oregon and California through similar long-term arrangements with cannabis licensees operating in these states
$MASN NEWS! Maison Luxe Announces Additional $250,000 Purchase Order from Signet International Group for Upcoming Holiday Season
https://www.globenewswire.com/news-release/2022/12/06/2568258/0/en/Maison-Luxe-Announces-Additional-250-000-Purchase-Order-from-Signet-International-Group-for-Upcoming-Holiday-Season.html
$PVSP We also invested in a small Korea based research entity, KRTL, to establish an early foothold in the rapidly expanding world of medical fungi, with a specific focus on Psilocybin. It is an entry to a large database of related research, various research entities actively involved in related development projects and provides Pervasip with a perfect perch to look at various fungi opportunities across the globe.
CGRA 5.8M VOLUME 10 DAY AVG_7.7M .162 +100%
CGRA 5.5M VOLUME 10 DAY AVG_7.7M .154 +90.12%
CGRA 4.5M VOLUME 10 DAY AVG_7.7M .148 +82.72%
CGRA 4M VOLUME 10 DAY AVG_7.7M .144 +77.78%
CGRA 3.7M VOLUME 10 DAY AVG_7.7M .139 +71.60%
CGRA 3.5M VOLUME 10 DAY AVG_7.7M .1284 +58.52%
CGRA 3.3M VOLUME 10 DAY AVG_7.7M .12125 +49.69%
CGRA 2.7M VOLUME 10 DAY AVG_7.7M .119 +46.91%
CGRA 529 VOLUME 10 DAY AVG_7.7M .094 +16.60%
CGRA .081 .0835 X .094
$PVSP in beautiful Port Townsend, on the northern end of the Olympic Peninsula, this gorgeous light deprivation greenhouse garden is producing beautiful flower and is home to some of the more exotic genetics in the Artizen brand. At 39,000 square feet it is the second largest of all of the gardens growing Artizen branded flower.
CGRA 17M VOLUME 10 DAY AVG_6.5M .0872 +58.69%
JNSH 3.8M VOLUME 10 DAY AVG_437K .005
*GAP FILLED
RJDG 12.6M VOLUME 10 DAY AVG_6.5M .009 +13.92%
CGRA 15M VOLUME 10 DAY AVG_6.5M .079 +43.77%
RJDG 12M VOLUME 10 DAY AVG_2.7M .0101 +27.85%
JNSH 2.8M VOLUME 10 DAY AVG_437K .0051 +2%
$SNPW >.01 receives $50M Insurance Wrap and Investment Grade "A " Rating thru Lloyds of London. (AKA Backstop)
https://fox4kc.com/business/press-releases/ein-presswire/602314646/50-million-insurance-via-a-investment-grade-underwriter-to-support-us-solar-manufacturing-plant-stock-symbol-snpw/
* Forecast Stock Price $2+ in approx 1-2 years.
BUZZ News about to hit watch for it.* Forecst Stock Price $2+ in approx 1-2 years. Do your own DD. Sharing info only.
ICYMI
CGRA 11.1M VOLUME 10 DAY AVG_6.5M .075 +36.49%
CGRA 11.M VOLUME 10 DAY AVG_6.5M .072 +31.03%
CGRA 10.7M VOLUME 10 DAY AVG_6.5M .07 +27.39%
CGRA 400K WALL .07 SLAPPED
CGRA 10.1M VOLUME 10 DAY AVG_6.5M .0699 +27.20%
CGRA 10M VOLUME 10 DAY AVG_6.5M .0695 +26.48%
CGRA 9.2M VOLUME 10 DAY AVG_6.5M .069 +25.57%
CGRA 8.8M VOLUME 10 DAY AVG_6.5M .067 +21.93%
CGRA 3.8M VOLUME 10 DAY AVG_6.5M .0659 +19.75%
CGRA 3.7M VOLUME 10 DAY AVG_6.5M .064 +16.47%
CGRA 3.2M VOLUME 10 DAY AVG_6.5M .0623 +13.38%
CGRA 3.2M VOLUME 10 DAY AVG_6.5M .062 +12.84%
CGRA 3.1M VOLUME 10 DAY AVG_6.5M .0614 +11.74%
CGRA 2.9M VOLUME 10 DAY AVG_6.5M .0602 +9.55%
$PVSP We also invested in a small Korea based research entity, KRTL, to establish an early foothold in the rapidly expanding world of medical fungi, with a specific focus on Psilocybin. It is an entry to a large database of related research, various research entities actively involved in related development projects and provides Pervasip with a perfect perch to look at various fungi opportunities across the globe.
$PVSP in beautiful Port Townsend, on the northern end of the Olympic Peninsula, this gorgeous light deprivation greenhouse garden is producing beautiful flower and is home to some of the more exotic genetics in the Artizen brand. At 39,000 square feet it is the second largest of all of the gardens growing Artizen branded flower.
$PVSP We also invested in a small Korea based research entity, KRTL, to establish an early foothold in the rapidly expanding world of medical fungi, with a specific focus on Psilocybin. It is an entry to a large database of related research, various research entities actively involved in related development projects and provides Pervasip with a perfect perch to look at various fungi opportunities across the globe.
$PVSP ZAM provides consulting, leasing, intellectual property licensing and other long-term arrangements to cannabis operators, including management of the Artizen™ brand assets
https://www.pervasip.net/zen-asset-management-zam
Traded at $1 plus before symbol change .. $1 or more possible again?
$PVSP We also invested in a small Korea based research entity, KRTL, to establish an early foothold in the rapidly expanding world of medical fungi, with a specific focus on Psilocybin. It is an entry to a large database of related research, various research entities actively involved in related development projects and provides Pervasip with a perfect perch to look at various fungi opportunities across the globe.
$PVSP We also invested in a small Korea based research entity, KRTL, to establish an early foothold in the rapidly expanding world of medical fungi, with a specific focus on Psilocybin. It is an entry to a large database of related research, various research entities actively involved in related development projects and provides Pervasip with a perfect perch to look at various fungi opportunities across the globe.
BCNN 11K VOLUME 10 DAY AVG_173K .03
$PVSP As one of Washington’s original cannabis brands, Artizen - branded products are the all-time fourth best-selling in Washington across all product categories, and the all-time third in flower. The commitment to quality and consistency behind Artizen™ has built a substantial following, fueling more than $69 million in wholesale sales to a distribution network with more than 200 retailers, corresponding to more than $200 million in retail value since inception in 2015. ZAM is looking to expand its service into Oregon and California through similar long-term arrangements with cannabis licensees operating in these states
wlan, with new ceo (with tmobile connection) is going to be one of the best plays of 2023!!$$
TPTW 53M VOLUME 10 DAY AVG_63M .0078 -24.11%
WLAN 15M VOLUME 10 DAY AVG_52M .0133 +24.30%
TPTW 9.7M VOLUME 10 DAY AVG_63M .0103
$PVSP Pervasip owns 100% of Artizen Corporation (“Artizen Corp”). Artizen Corp’s wholly owned subsidiary, Zen Asset Management LLC (“ZAM”) is a foundational operator that provides the basis for our cannabis related investments. ZAM, a diversified asset management company was founded to acquire, develop, and support companies and technologies in the cannabis industry.
BMXI 164K VOLUME 10 DAY AVG_151K .0915 +29.51%
$PVSP Pervasip Corp. (PVSP) is a developer of companies and technologies in high value emerging markets with a focus on cannabis and the medical use of fungi and psychedelics
That came out after close. Open could be fun:)
$CWBHF
$CWBHF+British American Tobacco(NYSE: $BTI )...C$2.00=$1.50USD...
Effective as of November 14, 2022, we entered into a subscription agreement with BT DE Investments, Inc. a wholly-owned subsidiary of BAT Group (LSE: BATS and NYSE: BTI), providing for the issuance of an approximately $56.8 million convertible debenture (the “Debenture”) is convertible into 19.9% ownership of the Company’s common shares at a conversion price of C$2.00 per common share of the Company on the Toronto Stock Exchange (TSX). The Debenture will accrue interest at an annualized rate of 5% until such time that there is federal regulation permitting the use of CBD as an ingredient in food products and dietary supplements in the United States. Following federal regulation of CBD, the annualized rate of interest shall reduce to 1.5%. The maturity date for the Debenture shall be November 2029. The Subscription Agreement contains customary representations and warranties and covenants. The funds from this Debenture can be used for operating purposes to fund the Company, as approved by the board of directors or in accordance with the Company’s board-approved budget.
$GOGY had back to back news last week! Here is the one from Tuesday - https://finance.yahoo.com/news/golden-grail-technology-otc-gogy-123000646.html
$GOGY indicated it has #BigPlan coming, please read the tweet here:
Our team has #BigPlans in store! 👀✨ #StayTuned #BusinessGrowth $GOGY #Leadership https://t.co/XbfLEsg2XC
— Golden Grail Beverages (@goldengrailbev) November 4, 2022
GDSI 4.4M VOLUME 10 DAY AVG_1.3M .029 +44%
GDSI 2.5M VOLUME 10 DAY AVG_1.3M .025 +22.13%
$NGTF is enjoying growing success in marketing its popular Nightfood brand of sleep friendly ice cream through a new hotel placement program.
Nightfood Continues to Capture Strong Share of Hotel Location Ice Cream Pint Sales
Tarrytown, NY, Nov. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Nightfood Holdings, Inc. (OTCQB: NGTF), the company pioneering the sleep-friendly nighttime snacking category, today announced that independent sales data for September and October across a subsection of qualifying hotel lobby marketplaces show that Nightfood ice cream pints are capturing a significant percentage of hotel ice cream pint sales from industry-leading Haagen Dazs.
The reporting subset represents all 30 hotels across the country which only sold 2 brands of pint ice cream (Nightfood and Haagen Dazs) during the two-month period and for which point-of-sale purchase data is available. Hotels which only sold Nightfood pints were excluded from the analysis, as were hotels that sold more than two brands of pints.
Nightfood, which began appearing nationally in hotel freezers less than six months ago, captured over 39% of total ice cream pint unit sales against the iconic Haagen Dazs which launched in 1960. In 33% of those hotels, Nightfood outsold Haagen Dazs, head-to-head.
"We've always believed that Nightfood would sell well in the high-margin hotel environment, and all the data to date supports that belief," commented Nightfood CEO Sean Folkson. "Hotels don't need to sacrifice revenue or profit when they add sleep-friendly snacks to their lobby shop assortments in support of guest wellness and sleep."
The Company, which recently added sleep-friendly cookies to their product line, believes any hotel selling snacks has an obligation to make sleep-friendly snacks available for their guests.
Folkson continued, "There are 56,000 hotels in the U.S., and we believe Nightfood should be in every one of them. We're proudly sharing this independent sales data with hotel decision-makers as we work to secure additional distribution commitments and timelines with some of the largest brands in the hotel industry."
About Nightfood
Nightfood is pioneering the category of sleep-friendly nighttime snacking.
Over 80% of Americans snack regularly at night, resulting in an estimated 700 million nighttime snack occasions weekly, and an annual spend on night snacks of over $50 billion. The most popular choices are ice cream, cookies, chips, and candy. Recent research confirms such snacks, in addition to being generally unhealthy, can impair sleep, partly due to excess fat and sugar consumed before bed.
Nightfood's sleep-friendly snacks are formulated by sleep and nutrition experts to contain less of those sleep-disruptive ingredients, along with a focus on ingredients and nutrients that research suggests can support nighttime relaxation and better sleep quality.
The brand is currently focused on establishing widespread national distribution of its sleep-friendly snacks in the high-margin hotel vertical. Nightfood began rolling into hotels across the United States in May 2022. Management believes hotels have an obligation to help guests achieve better sleep at every touchpoint, and one way to do that is through the snacks hotels curated for guests in hotel grab-and-go lobby shops.
With an estimated 56,000 hotels across the United States, national distribution is expected to lead to profitability, consumer adoption of the nighttime snack category, and a strategically defensible position from which category leadership can be maintained.
Questions can be directed to investors@Nightfood.com
By signing up at ir.nightfood.com, investors can receive updates of filings and news releases in their inbox.
Forward Looking Statements:
This current press release contains "forward-looking statements." Statements in this press release which are not purely historical (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects" and "estimates") are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future, including but not limited to, sales projections, potential customers, any products sold or cash flow from operations.
Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, (a) the inherent uncertainties associated with distribution of our products, (b) the market acceptance of our products at all levels of distribution and sale, including retail purchasers, wholesalers and hotel chains, (c) the success and commitment of our distribution partners to access distribution channels and successfully engage with sellers of our products, including, supermarkets and hotel chains, and our success in obtaining purchase orders from hotel chains, supermarkets and others, (d) competition from existing and new companies and products and (e) difficulties associated with obtaining financing on acceptable terms . These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our most recent annual report for our last fiscal year, our quarterly reports, and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
Media Contact:
Simon Dang
simon@nightfood.com
718-635-2949
Investor Contact:
Stuart Smith
SmallCapVoice
investors@nightfood.com
888-888-6444, x3
GDSI 78K VOLUME 10 DAY AVG_984K .0139
$GOGY very informative website - https://www.goldengrailbeverages.com/
WLAN 73M VOLUME 10 DAY AVG_40M .0106 +18%
Followers
|
439
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
27511
|
Created
|
02/26/13
|
Type
|
Free
|
Moderator OCKHAM'S RAZOR | |||
Assistants |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |